On October 6, 2022 Domain Therapeutics ("Domain" or "the Company"), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology, reported that it will present data on its proprietary GPCR programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (STIC) Annual Meeting, taking place on 8-12 November 2022 in Boston, US (Press release, Domain Therapeutics, OCT 6, 2022, View Source [SID1234622444]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Domain will present two posters on its oral small molecule EP4R antagonist, DT-9081. The first poster will highlight preclinical data illustrating the synergy of DT-9081 in combination with immune checkpoint inhibitors in different cancer models. The second poster will focus on the clinical trial design for the upcoming Phase I clinical study, which is expected to start before the end of the year.
Domain will also present a poster on its CCR8 depleting-antibody program illustrating key differentiating properties of its patent-protected proprietary series of antibodies targeting CCR8. It’s known that this GPCR is specifically expressed on tumor-infiltrating regulatory T cells, a highly immuno-suppressive cell population driving tumor progression. This target is currently attracting significant interest for the development of novel game-changing immunotherapies.
Dr. Stephan Schann, VP Research at Domain Therapeutics, commented: "The data to be presented will highlight the potential of our proprietary GPCR programs as attractive immuno-oncology drug candidates. We look forward to presenting these exciting new findings which will demonstrate the potential advantages of our drug candidates, whilst positioning Domain Therapeutics as key player in the field of immunotherapies."